Investigating the long-term effects of early HIV treatment on immune health
Longitudinal analysis of HIV reservoir and type I/III interferon system in people with HIV who initiated ART during primary infection
This study is looking at how starting HIV treatment early can help keep your immune system healthy in the long run, and it’s for people living with HIV who want to understand how their treatment might affect their overall health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11099901 on NIH RePORTER |
What this research studies
This research examines how starting antiretroviral therapy (ART) during the early stages of HIV infection impacts long-term immune health. By analyzing blood samples from individuals who began treatment early, the study aims to understand the relationship between immune activation and the size of the HIV reservoir over time. The researchers will focus on specific immune pathways that may remain activated even after successful treatment, which could lead to new strategies for managing chronic inflammation in people living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently been diagnosed with HIV and have started antiretroviral therapy during the early stages of their infection.
Not a fit: Patients who have been living with HIV for a long time and have not initiated ART during the early phase of infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance immune health and reduce complications for individuals living with HIV.
How similar studies have performed: Previous research has shown that early initiation of ART can lead to significant public health benefits, suggesting that this approach may yield valuable insights into long-term health outcomes.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Mackelprang, Romel D — University of Washington
- Study coordinator: Mackelprang, Romel D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.